RGC HealthcareBeta data

Regencell Bioscience Holdings Limited

$6.15-2.23%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Hong Kong
Market cap: 3.0B USD
Enterprise value: 3.0B USD
Full-time employees: 10

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.43 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.42 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.43 vs peers 0.63) and less liquidity (current ratio 1.42 vs peers 2.59)
Not enough data: growth

Would rank #1,144 of 1,157 fully scored healthcare companies (bottom 2%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Not profitable yet. Reported a loss over the last 12 months.
Regencell Bioscience reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 16 months ago.
The latest financial period we have ended 16 months ago, so the scores may not reflect recent results.
More volatile share price. Beta 1.43: tends to move more than the market.
Regencell Bioscience's shares have swung more with the market than most peers' (beta 1.43, above the market's 1.0).

StockQuotient Score

11/ 100

Oct 5 11 → Nov 4 11

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

0/100

Weak

2/3 inputs reported · Partial data

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-0.2%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-0.2%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield0.0%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

10/100

Weak

2/3 inputs reported · Partial data

Since last year: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-62.3%

SEC filings · 12 months to Jun 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-122.0%

SEC filings · 12 months to Jun 2025Reported value33% base weight · Z-score -12.62Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-177.7%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.43

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.38Sector median: 0.6250 · MAD: 0.3380

Current ratio1.42×

Yahoo FinanceReported value33% base weight · Z-score -0.85Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.32×

Yahoo FinanceReported value33% base weight · Z-score -0.47Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Regencell Bioscience

Is Regencell Bioscience getting weaker?: Its latest SEC filing (Oct 7, 2026) showed no major changes. Its overall score is unchanged at 11/100 since Oct 28, 2026.
How is Regencell Bioscience valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -0.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.2% vs peers 1.5% (weaker than 100% of peers).
Is Regencell Bioscience growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Regencell Bioscience?: Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on assets -62.3% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -62.3% vs peers 1.7% (weaker than 100% of peers).
How risky is Regencell Bioscience?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.43 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.43 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Jun 30, 2026 · filed Oct 7, 2026 · compared with the year ended Jun 30, 2025

No major changes

Worth watching: Regencell Bioscience is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous year	Latest year	Change
Net income (12 months)	−3.6M USD	−11.7M USD	+226.5%
Cash	2.4M USD	14.2M USD	+486.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Jun 2022	FY Jun 2023	FY Jun 2024	FY Jun 2025	FY Jun 2026	Change
Return on assets (ROA)	-41.3%	-46.5%	-51.0%	-62.3%	-79.4%	▼ 17 pts
Return on equity (ROE)	-43.6%	-48.8%	-52.3%	-73.7%	-87.7%	▼ 14 pts
Current ratio	28.46×	19.15×	41.92×	7.39×	10.77×	▲ 46%

RGC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.43 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.42 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.43 vs peers 0.63) and less liquidity (current ratio 1.42 vs peers 2.59)

Not enough data: growth

Would rank #1,144 of 1,157 fully scored healthcare companies (bottom 2%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Not profitable yet. Reported a loss over the last 12 months.

Regencell Bioscience reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 16 months ago.

The latest financial period we have ended 16 months ago, so the scores may not reflect recent results.

More volatile share price. Beta 1.43: tends to move more than the market.

Regencell Bioscience's shares have swung more with the market than most peers' (beta 1.43, above the market's 1.0).

Questions investors ask about Regencell Bioscience

Is Regencell Bioscience getting weaker?

Its latest SEC filing (Oct 7, 2026) showed no major changes. Its overall score is unchanged at 11/100 since Oct 28, 2026.

How is Regencell Bioscience valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -0.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.2% vs peers 1.5% (weaker than 100% of peers).

Is Regencell Bioscience growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Regencell Bioscience?

Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on assets -62.3% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -62.3% vs peers 1.7% (weaker than 100% of peers).

How risky is Regencell Bioscience?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.43 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.43 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Net income (12 months)

−3.6M USD

−11.7M USD

+226.5%

Cash

2.4M USD

14.2M USD

+486.7%

Key ratios

FY Jun 2022

FY Jun 2023

FY Jun 2024

FY Jun 2025

FY Jun 2026

Change

Return on assets (ROA)

-41.3%

-46.5%

-51.0%

-62.3%

-79.4%

▼ 17 pts

Return on equity (ROE)

-43.6%

-48.8%

-52.3%

-73.7%

-87.7%

▼ 14 pts

Current ratio

28.46×

19.15×

41.92×

7.39×

10.77×

▲ 46%